Skip to main content
C

CALIWAY BIOPHARMACEUTICALS CO., LTD. — Investor Relations & Filings

Ticker · 6919 LEI · 984500D2D587B98A7B13 TW Professional, scientific and technical activities
Open in API
Filings indexed 48 across all filing types
Latest filing 2026-04-10 Notice of Dividend Amou…
Country TW Taiwan
Listing TW 6919

About CALIWAY BIOPHARMACEUTICALS CO., LTD.

https://www.caliwaybiopharma.com

Caliway Biopharmaceuticals Co., Ltd. is a clinical-stage company specializing in the discovery and development of small-molecule therapeutics for medical aesthetics and chronic inflammatory diseases. The company focuses on high-value markets with significant unmet medical needs, utilizing unique pharmacological mechanisms to create niche products. Its lead candidate, CBL-514, is a first-in-class injectable drug designed to induce adipocyte apoptosis for non-surgical local fat reduction, cellulite, and the treatment of Dercum’s disease. Other pipeline assets include CBA-539, a long-acting injectable for pigmentation and anti-aging, and CBF-520, which targets central obesity and visceral fat reduction. Caliway aims to redefine aesthetic medicine and inflammatory disease management through innovative, non-invasive treatments that offer improved safety and efficacy over existing therapies.

Recent filings

Filing Released Lang Actions
115年第1季股利金額(董事會決議)
Notice of Dividend Amount Classification · 1% confidence The document is a detailed table of the company’s dividend distribution for a specific quarter, showing dividend per share, record dates, amounts available, and the board’s resolution on dividend allocation. This matches the definition of a Notice of Dividend Amount (DIV). It is not an annual or interim report, nor an announcement of a report; it is the actual dividend distribution notice.
2026-04-10 Chinese
115年第1季財務報告書 — 202601_6919_AI1.pdf
Regulatory Filings
2026-04-10 Chinese
公告本公司董事會通過115年第一季合併財務報告
Report Publication Announcement Classification · 1% confidence The document is a short regulatory filing from the Taiwan Stock Exchange's 'Market Observation Post System' (公開資訊觀測站). It announces that the company's board of directors has approved the Q1 financial report. While it contains summary financial data, it is a standard announcement form (a 'menu' rather than the 'meal') used to notify the public of the report's approval and key highlights, rather than the full comprehensive financial report itself. According to the 'Menu vs Meal' rule and the nature of this regulatory disclosure form, it is classified as a Report Publication Announcement. Q1 2026
2026-04-10 Chinese
公告本公司公司治理主管異動
Board/Management Information Classification · 1% confidence The document is a public disclosure from a stock exchange disclosure platform (公開資訊觀測站), announcing a change in the company governance officer (people and titles, effective dates, reasons). This matches an announcement of changes in senior management or board-level roles, fitting the Board/Management Information category (MANG).
2026-04-10 Chinese
115年3月背書保證與資金貸與
Regulatory Filings Classification · 1% confidence The document is a Taiwan MOPS disclosure showing tables of funds lent and guarantees (endorsements) with zero balances. It is neither an earnings release nor a management report; rather, it is a routine regulatory filing providing contingent liabilities information. This falls under the generic “Regulatory Filings” category as it is a periodic disclosure of guarantee and loan balances.
2026-04-09 Chinese
115年3月營業收入
Regulatory Filings Classification · 1% confidence The document is a monthly revenue summary disclosure from Taiwan’s Market Observation Post System (MOPS), showing net operating revenues for March (ROC Year 115) with comparative figures and accounting notes. It is an actual regulatory data filing rather than an earnings release (it’s a raw revenue table, not a Management’s Discussion) or an Interim/Quarterly Report (which would be more comprehensive). There’s no indication of an attached report or notice of publication. This falls under miscellaneous regulatory filings. Thus, the correct category is Regulatory Filings (RNS).
2026-04-09 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.